ArticleJournal of translational medicine2018
Correction to: Gamma-delta (γδ) T cells: friend or foe in cancer development?
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- γ-Secretase inhibitor ameliorates thyroid autoimmune damage via blocking Notch1 signaling and reducing γδT17 cells in EAT mice.Endocrine journal · 2026Article
- KRT17 promotes triple negative breast cancer through activation of Wnt signaling and γδ T-cells recruitment.Communications biology · 2026Article
- Can antioxidants' supplementation modulate the impact of dietary deoxynivalenol and zearalenone co-contamination on the systemic and mucosal immune response of weaned pigs?Journal of animal science · 2026Article
- Profiling T Cell Receptor and Immunoglobulin Repertoires Through RNA Sequencing to Understand Host Response to Trypanosoma cruzi Infection.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Emerging Strategies for Targeting Angiogenesis and the Tumor Microenvironment in Gastrointestinal Malignancies: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The TCR and LCK: foundations for T-cell activation and therapeutic innovation.Frontiers in immunology · 2025Review
- Allogeneic CAR-T cells for cancer immunotherapy.Immunotherapy · 2024Review
- Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells.Journal of Taibah University Medical Sciences · 2021Article
- Preservation of cell-based immunotherapies for clinical trials.Cytotherapy · 2019Review
Corrections and comments
- Erratum for
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following publication of the original article [1], the authors reported that they omitted to state that parts of Fig. 2 were adapted from Van Acker et al. [2] published by Taylor & Francis Ltd ( www.tandfonline.com ). The authors apologise for this omission. Figure 2 and its corrected caption are given below.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.